Stockreport

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Biologics Inc. - Common Shares  (ABCL) 
PDF Preclinical data on AbCellera’s PSMA x CD3 T-cell engagers demonstrate potent anti-tumor activity and potential to further enhance function through costimulatory strateg [Read more]